Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PC-SPES lessons

This article was originally published in The Tan Sheet

Executive Summary

Investigators studying herbals "should consider regular quality control evaluations" by independent labs in wake of contamination saga, NCI Office of Cancer & Complementary & Alternative Medicine Director Jeffrey White, MD, advises in Sept. 4 Journal of the National Cancer Institute. Editorial accompanies article by U.S./Czech team reporting presence of diethylstilbestrol, indomethacin in BotanicLab supplement manufactured from 1996 through mid-2001; warfarin was found in lots produced after July 1998. Diethylstilbestrol, indomethacin levels gradually declined after mid-1999, coinciding with "twofold to sixfold" drop in PC-SPES' antineoplastic potency. Origin of three synthetic drugs is "puzzling," researchers say. Preliminary findings were released in April (1"The Tan Sheet" April 15, 2002, p. 15)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094511

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel